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Abstract
Community-acquired pneumonia (CAP) is the infectious disease with the
highest number of deaths worldwide. Nevertheless, its importance is often
underestimated. Large cohorts of patients with CAP have been established
worldwide and improved our knowledge about CAP by far. Therefore, current
guidelines are much more evidence-based than ever before. This article
discusses recent major studies and concepts on CAP such as the role of
biomarkers, appropriate risk stratification to identify patients in need of
hospitalisation or intensive care, appropriate empiric antibiotic therapy
(including the impact of macrolide combination therapy and antibiotic
stewardship), and CAP prevention with novel influenza and pneumococcal
vaccines.
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Introduction and epidemiology
Community-acquired pneumonia (CAP) remains a burden in the 
modern world. The annual incidence ranges from between 2.7 and 
10 per 1000 persons and has not changed much during the last few 
decades1. In Germany, around 250,000 patients are hospitalised 
because of CAP each year, and it is expected that twice as many 
patients with CAP are managed in primary care2. The incidence 
shows a U-shaped distribution from very young to very old age3. 
CAP is still one of the most important reasons for premature death, 
particularly in developing countries and in children4.
CAP is an infectious disease of the lung parenchyma and adja-
cent organs. Respiratory bacteria constitute the major group of 
causative organisms. However, there must be some caution, as in 
most studies in more than 50% of the cases no pathogen could be 
identified5. Streptococcus pneumoniae is the pathogen most fre-
quently identified throughout all studies and settings (outpatients, 
inpatients, and intensive care unit [ICU] patients with CAP)5–7. 
Haemophilus influenzae (HI) is also frequently detected in outpa-
tients (13%) but much less in hospitalised patients (6% to 7%)5. A 
possible reason is the high prevalence of HI in patients with chronic 
obstructive pulmonary disease (COPD)8, patients who are at high 
risk of developing CAP9. Another important group of pathogens is 
respiratory viruses, particularly in outpatients but also inpatients, 
much less in ICU patients5. New detection techniques such as 
multiplex-polymerase chain reaction allow better insight into the 
relevant spectrum of viruses involved10. This fast-track diagnostic 
also allows us to put pandemic virus emergence into perspective, 
as shown during the H1N1 pandemic, in which respiratory syncy-
tial virus and human metapneumovirus were the most prevalent 
viruses and only pandemic influenza virus A/H1N1 (2009), and 
not seasonal influenza virus, was detected11. Outside pandemics, 
seasonal influenza viruses cause yearly increases in CAP incidence 
and lead to increased mortality in patients co-infected with bacterial 
pathogens12,13. Another relevant group are the so-called “atypical” 
bacteria. Mycoplasma pneumonia is frequent in young patients 
with CAP (7% to 12%) and usually shows a benign course14,15. 
Chlamydophila pneumoniae historically has been reported to be 
a frequent pathogen mainly on the basis of serological assays. 
However, more recent research using molecular techniques found 
significantly lower detections rates (21% versus 3%, respectively)15. 
Legionella pneumophila has been identified as a causative pathogen 
with different frequencies5,16,17. It also occurs in outpatients, who com-
monly show a more favorable course of disease than inpatients16.
Biomarkers
Historically, pro-inflammatory biomarkers such as leucocyte count 
and C-reactive protein (CRP) are widely used in CAP. In most 
patients with CAP, these markers are elevated and show the highest 
levels in bacterial CAP, followed by atypical CAP and viral CAP18. 
In mixed (bacterial + viral) CAP, CRP levels seem to be highest but 
the predictive value is low19. However, an individual prediction of 
CAP aetiology is not possible18. Also, procalcitonin (PCT), which 
shows a very fast response during infections, is not able to predict 
aetiology of CAP18. However, PCT levels on admission can sup-
port the identification of severe outcomes of CAP and add to the 
prognostic properties of clinical risk score20. It has a higher prog-
nostic accuracy compared with CRP and leucocyte count21. This 
has been recently confirmed22. Interestingly, PCT levels can provide 
independent identification of patients at low risk of death within 
CRB-65 (confusion of new onset, respiratory rate of at least 
30 breaths per minute, blood pressure of less than 90 mmHg systo-
lic or diastolic blood pressure of 60 mmHg or less, and age of at 
least 65 years) classes21. Importantly, antibiotic pre-treatment has to 
be taken into account, as it influences the prognostic properties23.
A very recent study showed that the diagnostic accuracies of CRP 
and PCT are insufficient to confirm CAP if the diagnosis is estab-
lished by using a gold standard that includes thoracic computed 
tomography (CT) scan24. However, in primary care, the addition of 
CRP (optimal cutoff of more than 30 mg/L) improved the diagnosis 
of CAP in patients with typical signs and symptoms, whereas PCT 
did not add clinically relevant information25.
In the most comprehensive study on the prognostic properties of 
new CAP biomarkers (including mid-regional pro-adrenomedullin 
[MR-proADM], mid-regional pro-atrial natriuretic peptide [MR-
proANP], pro-arginine-vasopressin [copeptin], proendothelin-1 
[CT-proET-1], PCT, CRP, white blood cell count, and CRB-65 
score), MR-proADM, a cardiovascular biomarker, showed the 
best individual and a combination of CRB-65 with MR-proADM 
showed the best overall prognostic performance26,27.
Hyponatremia is common on admission among patients with CAP 
and was independently associated with mortality. The combination 
of sodium and pro-vasopressin and pro-ANP levels achieved the 
highest prediction of mortality in a recent analysis28.
A very simple but powerful biomarker is admission blood glucose 
(Glc). Already mildly elevated Glc levels were significantly asso-
ciated with an increased short-term mortality odds ratio (OR) of 
1.56 with further increases at higher Glc levels. Therefore, acute 
hyperglycaemia may identify patients in need of intensified care to 
reduce the risk of death from CAP29. Potentially along comparable 
mechanisms and independently of clinical scores and inflammatory 
biomarkers, increased serum cortisol levels have been associated 
with mortality in CAP30. On the other hand, admission hypoglycae-
mia has also been associated with increased short- and long-term 
mortality31, underlining the value of Glc as a useful biomarker.
Risk stratification
Prognosis
CAP shows a highly variable disease course; published mortality 
rates vary between less than 1% and more than 40% according to 
treatment setting, disease severity, age, and comorbidities5. Whereas 
mortality and complication rates remain low in non-severe CAP 
managed in the community32, hospitalised CAP is associated with 
a high risk of respiratory failure or sepsis-related organ dysfunc-
tion. CAP mortality of hospitalised patients in Germany continues 
to be about 13%, rising to more than 35% in patients with need of 
mechanical ventilation2. Although treatment restrictions and func-
tional status of multi-morbid patients might influence such mortal-
ity figures33, even after conservative estimates excluding all patients 
residing in nursing homes or being bedridden before the CAP event, 
mortality remains more than 7%, which matches mortality rates of 
other recognised medical emergency conditions such as ST-elevation 
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myocardial infarction34. This tremendous prognostic spectrum 
requires timely and adequate risk stratification as a crucial first 
step in CAP management to determine level of care and treatment 
intensity. From a clinical perspective, risk stratification is divided 
into two major components: (1) identification of patients with a low 
complication risk in the outpatient setting suitable for ambulatory 
treatment and (2) identification of patients with high risk for acute 
organ failure necessitating early intensified management and moni-
toring interventions in the emergency department.
Predicting low risk of complications in the outpatient setting
To assist clinical risk assessment, different score systems have been 
recommended by guidelines. Most established are the pneumonia 
severity index (PSI) score35, consisting of 20 clinical, laboratory, 
and radiographic variables, and the CRB-65 or CURB criteria, 
which include only four parameters32,36. They proved to be compa-
rable tools for mortality prediction37,38, but the CRB-65 score is pre-
ferred in the outpatient setting, as it is easy to calculate and works 
without laboratory parameters. However, its sensitivity in elderly 
and multi-morbid patients is suboptimal, and poor functional status 
has been shown as a major independent mortality predictor for these 
patients in a recent analysis33. Additionally, pre-existing chronic 
comorbidities have been independently associated with adverse 
prognosis in CAP2,35,39–42. In particular, acute cardiac complica-
tions are of major prognostic impact41,42. Therefore, the absence of 
(potentially) decompensating comorbidities is another precondition 
for ambulatory treatment. Recent studies identified poor oxygena-
tion as an independent predictor for complications and mortal-
ity despite a low CRB-65 score43–45. Accordingly, a score adding 
poor oxygenation (saturation of less than 90%) and potentially 
decompensating comorbidities to the CRB-65 criteria recently 
has been introduced and validated in a large study from the 
CAPNETZ cohort, showing superior low-risk prediction compared 
with the original criteria39,40,46. The resulting risk evaluation to 
identify patients suitable for ambulatory treatment in the outpatient 
setting is depicted in Table 1.
Identifying high-risk patients in need of intensified 
management in the emergency department
Acute pulmonary or extra-pulmonary organ dysfunction due to 
sepsis or decompensating (especially cardiovascular) comorbidi-
ties determines early prognosis in CAP41,47–49. Organ dysfunction 
risk is highest within the first 3 days after hospitalisation2,41,48,50,51. 
Efforts have been made to characterise a subgroup with an “emer-
gency presentation” of CAP defined by a high risk of early clinical 
deterioration in order to target intensified management interven-
tions to patients with a high potential of prognosis improvement47,52. 
A management-based risk stratification to allocate interventions 
like monitoring of organ functions, guideline-concordant man-
agement of severe sepsis, and early parenteral antimicrobial com-
bination treatment has been suggested45,53. Obviously, patients 
presenting with immediate need for mechanical ventilation or vaso-
pressor treatment are identified as medical emergencies. However, 
a recent analysis from the CAPNETZ cohort showed that progno-
sis is poorest in patients not presenting with these “major criteria” 
but deteriorating in the short course of the disease47. Independent 
predictors for early deterioration were vital sign abnormalities 
at presentation, highlighting the need for careful clinical patient 
evaluation. Recent studies have shown that the American Thoracic 
Society/Infectious Diseases Society of America (ATS/IDSA) minor 
criteria, which represent parameters of acute organ dysfunction, 
improve high-risk prediction47,54–56. Their accuracy to predict organ 
replacement therapy (optimal cutoff > two criteria) has been con-
firmed in a meta-analysis56, and outcome improvement after man-
agement intensification guided by these criteria in the emergency 
room has been demonstrated in an interventional trial57. Therefore, 
clinical high-risk identification should focus on acute respiratory or 
extra-pulmonary sepsis- or comorbidity-associated organ dysfunc-
tion, and careful clinical evaluation should be complemented by 
regular assessment of vital sign abnormalities and the minor criteria 
as shown in Table 2.
Adjuvant treatment
Despite adequate antimicrobial therapy, approximately 10% of all 
patients with CAP will not survive their current pulmonary infec-
tion, and mortality rates for severe CAP levelled off at 20% to 30% 
for the last few decades, especially if treatment failure occurs58. An 
overwhelming immunological response is assumed to be one of the 
key pathophysiological mechanisms behind the stagnating mortal-
ity rates. Keeping in mind the empty pipeline for new antimicrobial 
agents and the increasing threat of antibiotic resistance, adjuvant 
therapeutic strategies beyond just killing the causative microbes 
are urgently needed and are now the focus of research. Medici-
nal modulation or suppression of the immunologic host response 
(e.g. by the application of corticosteroids) might be a valid approach. 
This concept has been successfully implemented in the treatment 
of different infectious conditions such as bacterial meningitis and 
septic shock.
Following the first positive corticosteroid trial in CAP by 
Confalonieri et al.59, conflicting results mainly from small clini-
cal trials and meta-analysis questioned the potential benefit, and 
systematic reviews asked for larger randomised trials60–62. In 2015, 
two randomised controlled trials (RCTs) of adequate sample size 
Table 1. Low-risk identification in the outpatient setting.
Clinical assessment, supplemented by evaluation of the following criteria:
•   Respiratory rate of less than 30 per min
•   Diastolic/systolic blood pressure of at least 61 mm Hg/90 mm Hg
•   No new-onset mental confusion
•   Oxygen saturation of at least 90% on room air
•   No (potentially) decompensating comorbidity
•   No poor functional status (“chronically bedridden”)
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were published, readopting the concept of adjuvant corticosteroid 
treatment in CAP63,64. Both studies appear to be supportive of 
corticosteroid administration, but before changing clinical practice, 
it is worth taking a closer look at their findings.
Blum et al. randomly assigned hospitalised patients with CAP 
(n = 785; 70% PSI III-V) to receive an adjuvant treatment with 
50 mg prednisolone daily in addition to standard care63. The pri-
mary endpoint of this study was time to clinical stability and it was 
reached 1.4 days earlier in the treatment group (3.0 versus 4.4 days, 
hazard ratio [HR] 1.33, P <0.001). Additionally, steroid adminis-
tration facilitated an earlier switch to oral sequence therapy (4.0 
versus 5.0 days, P = 0.011), shortened the length of hospitalisation 
(6.0 versus 7.0 days, HR 1.19, P = 0.012), and reduced the incidence 
of pneumonia-associated complications like acute respiratory dis-
tress syndrome (ARDS) and empyema (OR 0.46, 95% confidence 
interval [CI] 0.22 to 0.98, P = 0.05). These effects were independ-
ent of PSI score at admission, initial levels of CRP, and underlying 
comorbidities such as COPD. Unfortunately, the study was 
not designed to address mortality, the most important clinical 
outcome, and the number of side effects (hyperglycemia) was sig-
nificantly higher in the treatment group (19% versus 11%, OR 1.96, 
P = 0.001). Furthermore, overall mortality was comparably low 
(3.4%) and only few patients required ICU treatment (4.8%).
The second study, by Torres et al., included 120 CAP patients with 
high serum levels of inflammatory markers (CRP >150 mg/L)64. 
The patients were randomly assigned to receive 0.5 mg/kg methyl-
prednisolone given twice a day for 5 days or placebo. The primary 
endpoint was occurrence of treatment failure, a composite endpoint 
including early failure (progression to septic shock, the need for 
mechanical ventilation, or death within 72 hours after admission) 
and late failure (radiographic progression, persisting respiratory 
failure, progression to septic shock, the need for mechanical ven-
tilation, or death within 72 to 120 hours after admission). The 
authors found significantly less treatment failure in the treatment 
group (13% versus 31%, P = 0.02) and by trend a lower mortality. 
Again, the incidence of hyperglycemia was higher, but not sta-
tistically significant (18% versus 12%, P = 0.34). Although the 
results were positive at first sight, a critical interpretation is rec-
ommended. The composite endpoint “treatment failure” allows for 
misinterpretations, especially when considering that the only sig-
nificant differences between the groups were found in “late failure” 
due to “radiographic progression” and “late-onset septic shock”. 
“Radiographic progression” alone does not necessarily reflect clini-
cal failure; it needs to be accompanied by clinical instability to be 
indicative of treatment failure, and “late-onset septic shock” is not 
always attributable to CAP.
In conclusion, there is growing evidence of some beneficial effects 
of steroid treatment in terms of faster resolution of clinical signs 
and symptoms and prevention of CAP-associated complications, 
but so far the impact on mortality cannot be judged sufficiently. 
This was confirmed by a recent meta-analysis indicating that ster-
oids had no significant impact on mortality (relative risk [RR] 0.72, 
95% CI 0.43 to 1.21), even in severe CAP (RR 0.72, 95% CI 0.43 
to 1.21), but may prevent the development of ARDS (RR 0.21, 
95% CI 0.08 to 0.59) and reduce the lengths of hospital and ICU stay 
and the time to clinical stability65. Hopefully, the results of ongo-
ing trials will help to elucidate the future role of adjuvant corticos-
teroid treatment in the management of CAP66,67. Nevertheless, it is 
important to notice that supportive steroid treatment in patients with 
influenza CAP is associated with increased mortality68. Therefore, 
steroids should not be administered to patients with proven influ-
enza, except for asthmatics and COPD patients who may require 
systemic steroids for the treatment of bronchial obstruction, even in 
the context of influenza69.
Recently, it has been reported that statins may have immunomodu-
latory and anti-inflammatory properties and that their current intake 
may have favourable effects on the course of respiratory infec-
tions, including pneumonia70,71. However, most of the knowledge 
Table 2. High-risk identification in the emergency department (including assessment of the ATS/IDSA 
minor criteria).
Clinical assessment, supplemented by evaluation of the following criteria:
•   Presence of acute respiratory failure
     ○ Respiratory rate of 30/min or more
     ○ Arterial oxygen partial pressure/fractional inspired oxygen (paO2/FiO2) of 250 or less
     ○ Oxygen saturation of less than 90%
     ○ Multi-lobar infiltrate
•   Presence of acute extra-pulmonary organ dysfunction
     ○ Systolic blood pressure of less than 90 mm Hg/hypotension requiring aggressive fluid resuscitation
     ○ Elevated lactate
     ○ Temperature of less than 36°C
     ○ New-onset mental confusion
     ○ Acute renal failure/blood urea nitrogen of more than 20 mg/dL
     ○ Leucocytes of less than 4000/µL
     ○ Thrombocytes of less than 100,000/µL
•   Presence of instable comorbidity
     ○ Especially acute cardiovascular complication
ATS/IDSA, American Thoracic Society/Infectious Diseases Society of America.
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is derived from retrospective case-control studies including patients 
with already-established statin intake, and only few prospective 
RCTs are available.
In one large, population-based, case-control study (n >100,000), the 
recent use of statins significantly reduced the risk of mortality from 
pneumonia (adjusted OR 0.47) but had an effect neither on the inci-
dence of non-severe pneumonia in the study population nor on the 
need for hospitalisation due to pneumonia72. Two additional case-
control studies found a 22% reduced risk of pneumonia in patients 
with current exposure to statins73,74. However, the protective effect 
was not shown in other studies, possibly indicating a “healthy user” 
bias75,76.
One recent randomised, double-blind, placebo-controlled trial 
addressed the effects of de novo statin use on CAP outcome and 
blood levels of inflammatory cytokines77. In this study, the use of 
20 mg simvastatin once daily for 4 days since hospital admission 
did not reduce the time to clinical stability and the levels of inflam-
matory cytokines in patients hospitalised with CAP. However, it is 
worth mentioning that the authors failed to achieve their recruit-
ment target for determining the effect of de novo statin use on their 
clinical endpoint (time to clinical stability). Another randomised, 
double-blind, placebo-controlled trial focused on the effects of sim-
vastatin (60 mg daily) on day 28 mortality in patients with ventilator- 
associated pneumonia78. This study was prematurely stopped for 
futility after interim analyses with 300 patients enrolled. There was 
no difference in the primary endpoint (day 28 mortality) between 
groups (statin group 21.2% versus placebo group 15.2%, P = 0.1).
In conclusion, there is some evidence indicating that an established 
statin exposure may reduce the risk of pneumonia and have benefi-
cial effects on the clinical course, but the results are conflicting and 
the findings of first RCTs on de novo statin use are discouraging. 
Therefore, the use of statins for primary prophylaxis or as adjuvant 
pneumonia therapy may not be recommended at present.
Antibiotic treatment
Most major guidelines suggest an empiric treatment stratified 
according to severity of disease79,80. Outpatients are treated orally 
with penicillins, macrolides, tetracyclines, or fluoroquinolones 
with anti-pneumococcal activity (i.e. moxifloxacin or levofloxacin). 
Oral cephalosporins have been linked to increased treatment failure 
(OR 2.86, 95% CI 1.56 to 5.27), probably due to the unfavourable 
bioavailability plus—compared with intravenous administration—
low licensed dosages81. Recent EUCAST (European Committee 
on Antimicrobial Susceptibility Testing) guidelines state (e.g. for 
HI) that cefuroxime breakpoints apply only to high-dose treatment 
(i.e. 1.5 g three times daily).
As outlined above, the proportion of “atypical” pathogens has been 
probably overestimated in the past, particularly due to the low 
specificity of serology for detection of Chlamydophila pneumoniae82.
Since coverage of atypical bacteria by macrolides, fluoroquinolones, 
or tetracyclines seems to be expandable in mild cases treated as 
outpatients—most guidelines recommend oral penicillins or ami-
nopenicillins (longer half life time, higher bioavailability, and 
better activity against HI than penicillin V) to cover pneumococci—
empiric combination treatment of inpatients with beta-lactam plus 
macrolide remains an issue of debate79,80.
Besides covering “atypical” pathogens, macrolides are supposed 
to attenuate the inflammatory response by decreasing expression 
of pro-inflammatory cytokines and consecutive neutrophil recruit-
ment to lung parenchyma. A retrospective study revealed a clinical 
advantage of macrolides even in patients with macrolide-resistant 
pneumococcal pneumonia. However, recently, the cardiotoxicity 
of macrolides has been linked to a slightly increased mortality. A 
meta-analysis found that erythromycin carries the greatest risk of 
QT prolongation and torsades de pointes from all macrolides, fol-
lowed by clarithromycin and azithromycin83. A large Danish cohort 
study estimated 37 cardiac deaths in 1 million treatments with 
clarithromycin84, with an increased risk particularly in women. 
Whereas the Svanstrom study addressed younger adults and not 
patients with CAP, the study by Ray et al. showed a higher risk of 
sudden death with azithromycin compared with amoxicillin85. The 
study by Schembri et al. is currently the only one that looked spe-
cifically at protocol-defined CAP and showed an increased risk of 
long-term cardiac events86. However, Mortensen et al. showed that 
the benefit of azithromycin in reducing CAP mortality outweighed 
the risk of cardiotoxicity87.
A 2014 meta-analysis comprising four prospective cohort stud-
ies and 12 retrospective cohort studies (n = 42,942) found a 
decreased mortality for macrolide/beta-lactams versus beta-lactam 
monotherapy88. However, randomised studies were not available.
Finally, in 2015, two randomised studies addressing this question 
were published. A cluster-randomised non-inferiority study from 
The Netherlands compared beta-lactam monotherapy, beta-lactam/
macrolide, and fluoroquinolone for empiric treatment of CAP89. A 
Swiss open-label, multi-centre, non-inferiority, randomised trial 
compared cefuroxime or amoxicillin/clavulanic acid with or without 
clarithromycin90. The Swiss study could not prove non-inferiority 
for beta-lactam monotherapy regarding the proportion of patients 
reaching clinical stability on day 7, even after exclusion of patients 
with a positive urine legionella antigen test result. In contrast, the 
Dutch study found that beta-lactam monotherapy was non-inferior 
to strategies with a beta-lactam-macrolide combination or fluo-
roquinolone monotherapy with regard to 90-day mortality. The 
macrolide used in the Dutch study was erythromycin91, which has 
a higher cardiotoxicity than azithromycin or clarithromycin83. The 
Swiss study showed that, in particular, patients with atypical patho-
gens (mostly Mycoplasma pneumoniae) and patients with a higher 
severity profited from the macrolide combination. This supports the 
obligated empiric beta-lactam/macrolide combination treatment for 
at least all CAP patients admitted to the ICU, a strategy suggested 
by most major guidelines80,81,91.
Antibiotic stewardship
Antibiotic stewardship has become an important strategy to fight 
the antibiotic resistance crisis. How is antibiotic stewardship 
implemented in CAP treatment? First of all, pneumonia has to be 
differentiated from non-pneumonia entities (e.g. bronchitis and 
acute exacerbation of COPD) in patients presenting with lower 
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respiratory tract infections. This requires a standard chest X-ray, 
which is frequently not available in the outpatient setting. Several 
studies have shown that using a PCT is a useful biomarker to decide 
for or against empiric antibiotics in inpatients and outpatients pre-
senting with lower respiratory tract infections. PCT-guided strate-
gies have decreased (unnecessary) antibiotic prescriptions by 30% 
to 50% without impairing clinical outcome92,93. Similar data are 
available in primary care for CRP, which—in contrast to PCT—is 
available as a point-of-care test94.
Other approaches used a clinical score to predict CAP in outpa-
tients presenting with acute respiratory tract infection in order to 
identify patients who should be prescribed antibiotics95.
Another strategy to decrease antibiotic consumption without harm-
ing the patient is to shorten antibiotic treatment. A recent prospec-
tive before-and-after intervention study from Scotland describes 
the implementation of a simple CRB-65-based algorithm for dura-
tion of treatment (i.e. CAP: 5 days of antibiotics for mild and 7 for 
moderate/severe cases. Acute exacerbation of COPD: 5 days of 
antibiotics and no antibiotics at all in patients without an increase 
in sputum purulence)96. This algorithm was enforced by automatic 
stop dates and pharmacist feedback to prescribers and resulted in 
significant reductions of antibiotic consumption and in antibiotic 
side effects without increasing mortality or length of stay.
Vaccination
Vaccines are available against pneumococci and influenza virus, 
the most frequent bacterial and viral causes of CAP, respectively. 
Bacterial-viral co-infections are associated with increased mor-
tality, and synergistic effects have been shown for combined 
vaccination12.
The standard influenza vaccine is the trivalent split vaccine, con-
taining two influenza A and one influenza B strains, which are 
annually selected by the World Health Organization. Within the last 
few years, efforts have been made to improve acceptance, coverage 
of the vaccine, and particularly its efficacy in the elderly. A cen-
tral problem of the influenza vaccine is that the elderly, who are at 
increased risk, exhibit an inferior response to the vaccine because of 
immunosenescence. Intradermal vaccination aims to stimulate more 
antigen-presenting cells, which are found in higher concentration in 
the dermis than in the subcutis or the muscle. Virions mimic natural 
viral cell entry, and adjuvants aim to recruit more antigen-presenting 
cells. High-dose vaccines use four times the amount of antigen. 
Whereas studies have shown that most of these approaches increase 
antibody titres, only high-dose vaccines were tested in a study with 
a clinically relevant endpoint and showed an increased prevention 
of laboratory-confirmed influenza cases97. Other strategies try to 
improve the influenza vaccine coverage. In contrast to influenza A, 
influenza B does not undergo antigenic shift and therefore does not 
cause pandemics. However, as a result of accumulated point muta-
tions, influenza B split into two lines (Yamagata and Victoria) about 
30 to 40 years ago98. Historically, only one influenza B line was 
included in the trivalent split vaccine. Therefore, the coverage of 
the trivalent split vaccine has depended on the accurate prediction 
of the dominating B line in the particular season. Recently, quadri-
valent influenza vaccines that include both influenza B lines have 
been made available for clinical use99.
Pneumococcal vaccination of adults is a current issue of debate, 
since both a 23-valent polysaccharide vaccine and a 13-valent con-
jugate vaccine are licensed for use in adults. Meta-analyses have 
shown that the polysaccharide vaccine prevents pneumococcal 
bacteraemia with an efficacy of about 75%. However, the major-
ity of pneumococcal pneumonia is non-bacteraemic, and it remains 
controversial whether this vaccine is protective against non-invasive 
pneumococcal pneumonia100. To date, only one RCT in Japanese 
nursing home residents showed a clear reduction of pneumococcal 
pneumonia101, whereas several other studies and a respective meta-
analysis revealed no effect100. In a recent meta-analysis comparing 
the four available RCTs on 23-valent polysaccharide pneumococ-
cal vaccine (PPV23) efficacy against CAP, the study by Maruyama 
et al.101 has been identified as an outlier, contributing statistically 
significant heterogeneity to this analysis102. Recently, a large Dutch 
placebo-controlled multi-centre study showed that the 13-valent 
conjugate vaccine prevented non-invasive pneumococcal pneumo-
nia due to vaccine serotypes with an efficacy of 45%103. The cov-
erage of 13-valent pneumococcal conjugate vaccine (PCV13) in 
adults is supposed to decrease because of herd protection effects of 
the PCV13 infant vaccination program that has led to a substantial 
decrease of the 13 vaccine serotypes in countries with such a pro-
gram. Nevertheless, it remains unclear whether the herd protection 
effects on invasive pneumococcal disease seen after implement-
ing PCV7 can be extrapolated to the additional six serotypes of 
PCV13 or non-invasive pneumococcal pneumonia or both. Recent 
data from Sweden, the US, and Germany suggest that there is only 
minor or no herd protection for serotype 3, one of the most fre-
quent serotypes causing pneumonia in adults104–106. Considering 
these data, the Advisory Committee on Immunization Practices has 
suggested a sequential vaccination (PCV13 followed by PPV23 
after 6 to 12 months) for all adults older than 65. Within the next 
few years, intensive surveillance on serotype distribution in pneu-
mococcal pneumonia is needed in order to estimate the extension 
of herd protection and to evaluate the use of PCV13 vaccination 
in adults.
Implications for clinical practice
CAP is the infectious disease with the highest number of deaths 
worldwide. Nevertheless, the importance of this disease is often 
underestimated. It is diagnosed too late, severity scoring is not 
appropriate, so that patients are too seldom admitted to intermediate 
care or ICUs, and antibiotic therapy is often not in accordance with 
guidelines. Large cohorts of patients with CAP have been estab-
lished worldwide and vastly improved our knowledge about CAP. 
Therefore, current guidelines are much more evidence based than 
ever before. The challenge for the future is to implement current 
knowledge into clinical practice to reduce the number of CAP cases 
(by vaccination) and the number of deaths (by adequate diagnostics 
and treatment). National and international societies should establish 
CAP audits to oversee the management of CAP and to give clini-
cians feedback about their daily clinical practice.
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